



**World Health
Organization**

WHO Target Product Profile COVID-19 Vaccines

Current considerations



R&D Blueprint

Powering research
to prevent epidemics

WHO Target Product Profile (TPP) for COVID-19 Vaccines

A WHO TPP describes the **preferred** and **minimally acceptable** attributes for human vaccines

- for long term protection of persons at high ongoing risk of COVID-19 such as healthcare workers and
- for reactive use in outbreak settings with rapid onset of immunity.

WHO Working Group Target Product Profiles for COVID-19 Vaccines

3

Constituted in April 2020, the objectives of this group are:

- To develop a global target product profile (TPP) for vaccines against COVID-19. The TPP will include preferred and minimally acceptable profiles for two types of vaccines:
 - Human vaccines – for long term protection of persons at high ongoing risk of COVID-19 such as healthcare workers.
 - Human vaccines – for reactive use in outbreak settings with rapid onset of immunity.
- To provide technical advice and support the WHO Secretariat through comments and or feedback from stakeholders

WHO Target Product Profiles for COVID-19 Vaccines

4

The Target Product Profile (TPP) was developed in **April 2020** through a consultation process with key experts.

It was intended to guide and prioritize the development of vaccines.

**As new scientific evidence is being generated,
this TPP is under review and revision.**

TPP key elements

Vaccine characteristics

- Indication for use
- Contraindications
- Target population
- Safety reactogenicity
- Measures of efficacy
- Dose regimen
- Durability of protection
- Route of administration
- Product stability
- Co- administration with other vaccines
- EUAL/WHO EUL
- Accessibility

<https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines>

Issues under discussion

What efficacy do we want? (immunogenicity, durability, variants, regardless of series, booster, etc.)

- Initial, after primary vaccination
- After booster doses

Considerations on attributes for vaccines for “outbreak response” and for “long term” use?

Separate section for pediatrics?

Further consider “availability” and access section to include (as preferred) firm commitments to actually make vaccine available for use around the world—

Other issues under discussion

- Onset of protection
- Pregnancy
- Immunosuppressed

- Vaccine Vial Monitors (VVMs) – most vaccines do not yet include this
- Storage temperature

- Long COVID

WHO Target Product Profiles for COVID-19 Vaccines

Process for review and adaptation

1. Working Group deliberations (ongoing)
2. Open consultation (draft version accessible in the WHO website)
3. Review of comments and preparation of final version by WG members